[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CR20230390A - Therapeutic composition based on dhodh- inhibiting neurolaena leaves for the treatment of rna virus infections - Google Patents

Therapeutic composition based on dhodh- inhibiting neurolaena leaves for the treatment of rna virus infections

Info

Publication number
CR20230390A
CR20230390A CR20230390A CR20230390A CR20230390A CR 20230390 A CR20230390 A CR 20230390A CR 20230390 A CR20230390 A CR 20230390A CR 20230390 A CR20230390 A CR 20230390A CR 20230390 A CR20230390 A CR 20230390A
Authority
CR
Costa Rica
Prior art keywords
neurolaena
dhodh
therapeutic composition
inhibiting
leaves
Prior art date
Application number
CR20230390A
Other languages
Spanish (es)
Inventor
Henry Joseph
Original Assignee
Phytobokaz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phytobokaz filed Critical Phytobokaz
Priority claimed from PCT/EP2022/053144 external-priority patent/WO2022171682A1/en
Publication of CR20230390A publication Critical patent/CR20230390A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y103/00—Oxidoreductases acting on the CH-CH group of donors (1.3)
    • C12Y103/98—Oxidoreductases acting on the CH-CH group of donors (1.3) with other, known, acceptors (1.3.98)
    • C12Y103/98001—Dihydroorotate oxidase (fumarate) (1.3.98.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Disclosed is a therapeutic composition comprising a mother tincture of a leaf extract of a plant of the genus "Neurolaena" and the species "lobata" for use as a drug inhibiting human dihydroorotate dehydrogenase (DHODH).
CR20230390A 2021-02-10 2022-02-09 Therapeutic composition based on dhodh- inhibiting neurolaena leaves for the treatment of rna virus infections CR20230390A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2101262A FR3119539B1 (en) 2021-02-10 2021-02-10 Therapeutic composition inhibiting DHODH
PCT/EP2022/053144 WO2022171682A1 (en) 2021-02-10 2022-02-09 Therapeutic composition based on dhodh- inhibiting neurolaena leaves for the treatment of rna virus infections

Publications (1)

Publication Number Publication Date
CR20230390A true CR20230390A (en) 2024-01-12

Family

ID=75278217

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230390A CR20230390A (en) 2021-02-10 2022-02-09 Therapeutic composition based on dhodh- inhibiting neurolaena leaves for the treatment of rna virus infections

Country Status (2)

Country Link
CR (1) CR20230390A (en)
FR (2) FR3119539B1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE382349T1 (en) * 1998-03-11 2008-01-15 Williams James W ANTIVIRAL USES OF LEFLUNOMIDE PRODUCTS
US6841561B1 (en) * 1999-10-01 2005-01-11 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
FR2870457B1 (en) * 2004-05-19 2006-07-14 Henry Joseph COMPOSITION FOR THE TREATMENT OF DISEASES CAUSED BY COOLINGS, AND / OR VIRAL INFECTIONS WITH RNA VIRUSES, AND / OR BY PROTOZOAR PARASITOSES

Also Published As

Publication number Publication date
FR3119539B1 (en) 2023-12-22
FR3119539A1 (en) 2022-08-12
FR3119540A1 (en) 2022-08-12
FR3119540B1 (en) 2024-10-04

Similar Documents

Publication Publication Date Title
WO2021207409A3 (en) Small molecule inhibitors of sars-cov-2 viral replication and uses thereof
MX2021007970A (en) 6-oxo-1,6-dihydropyridazine derivative, preparation method therefor and medical use thereof.
NO20053077L (en) Therapeutic formulations for the treatment of beta-amyloid-related diseases.
AU2003241345A1 (en) Use of mastic and its components for the control of microbial infections
WO2008022189A3 (en) Administration of high potency platinum compound formulations by inhalation
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
Sawant et al. Preventive aspect of ayurveda and yoga towards newly emerging disease COVID-19
BR0310061A (en) Methods for treating respiratory diseases and conditions with a selective inhibitor of inos and a inhibitor of pde and their compositions
Connolly et al. A fatal case of progressive vaccinia
CA2504872A1 (en) Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
CR20230390A (en) Therapeutic composition based on dhodh- inhibiting neurolaena leaves for the treatment of rna virus infections
DK1343472T3 (en) Thixotropic nasal spray
BR112022010733A2 (en) METHODS TO TREAT PAIN
WO2006058430A1 (en) Composition for treating hair and scalp and method for preparing same
BR0311180A (en) Methods for treating respiratory diseases and conditions using a selective inhibitor of inos
WO2005097618A3 (en) Low dose therapy for treating viral infections
CN1903214B (en) Ointment containing red precipitate
CN111840403A (en) Ear drops for tinnitus and having ear strengthening and relaxing functions
US20050058729A1 (en) Treatment for bacterial infections and related disorders
HUP0002154A2 (en) Use of famotidine for the preparation of pharmaceutical compositions treating depression or symptoms related with depression
Saleh et al. Effects of combination of Amphotericin B and Fumaria parviflora ethanolic extract against Leishmania major and expression of miR146a-5p and miR499 levels
MX2024003562A (en) Compositions and methods for enhancing and expanding infection induced immunity.
CN1191839C (en) Medicine for treating pulmonery tuberculosis
CN107095884A (en) A kind of Eradicates necrotic tissue and promoting muscle growings cream
CN1208063C (en) Chemical mixture and its use